Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
- Procopio G.
- Chiuri V. E.
- Giordano M.
- Alitto A. R.
- Maisano R.
- Bordonaro R.
- Cinieri S.
- Rossetti S.
- De Placido S.
- Airoldi M.
- Galli L.
- Gasparro D.
- Ludovico G. M.
- Guglielmini P. F.
- Carella C.
- Nova P.
- Aglietta M.
- Schips L.
- Beccaglia P.
- Sciarra A.
- Livi L.
- Santini D.
- Procopio G.
- Chiuri V.
- Mantini G.
- Roberto Bordonaro R. M.
- Cinieri S.
- Rossetti S.
- De Placido S.
- Airoldi M.
- Galli L.
- Gasparro D.
- Ludovico G. M.
- Guglielmini P. F.
- Santini D.
- Naglieri E.
- Fagnani D.
- Aglietta M.
- Livi L.
- Schips L.
- Passalacqua R.
- Fiore M.
- D'Angelillo R. M.
- Ceresoli G. L.
- Magrini S.
- Rondonotti D.
- Mirone V.
- Ferriero M. C.
- Sciarra A.
- Acquati M.
- Boccardo F.
- Scagliotti G. V.
- Mencoboni M.
- De Giorgi U.
- Micheletti G.
- Lanzetta G.
- Sartori D.
- Carlini P.
- Soto Parra H. J.
- Battaglia M.
- Uricchio F.
- Bernardo A.
- De Lisa A.
- Carrieri G.
- Ardizzoia A.
- Aieta M.
- Pisconti S.
- Marchetti P.
- Paiar F.
DOIAbstract
Background: Limited real-world data exist on the effectiveness and safety of abiraterone acetate plus prednisone (abiraterone hereafter) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy. Most of the few available studies had a retrospective design and included a small number of patients. In the interim analysis of the ABItude study, abiraterone showed good clinical effectiveness and safety profile in the chemotherapy-naive setting over a median follow-up of 18 months. Patients and methods: We evaluated clinical and patient-reported outcomes (PROs) of chemotherapy-naive mCRPC patients treated with abiraterone as for clinical practice in the Italian, observational, prospective, mu...
Add to ORKG